Helpful Hints for Use of Biosimilars in Ophthalmology Practices
Dr Peter Kaiser shares helpful hints for patient communication and for including biosimilars in clinical practice.
Challenges in Use of Biosimilars in Ophthalmology Practices
An ophthalmologist discusses challenges and concerns that physicians might face when using biosimilars for retinal diseases.
CHS-201 and Other Ranibizumab Biosimilars in Ophthalmology
Dr Peter Kaiser provides an overview of biosimilars that are either approved or are being developed for treatment of retinal diseases.
Clinical Studies for Biosimilars in Ophthalmology
Dr Kaiser shares critical differences in primary outcome readout in clinical studies for biosimilars vs reference products for retinal diseases.
Approval Process and Quality of Biosimilars
Dr Peter Kaiser outlines approval process of biosimilars and highlights key differences from approval process of reference products.
Overview of Biosimilars
An ophthalmology expert provides an overview of biosimilars and their potential in ophthalmology practices.
2 Clarke Drive Cranbury, NJ 08512